The Oral Psoriasis Race Just Got Serious: What Takeda's Zasocitinib Data Mean for Autoimmune Treatment
For years, the psoriasis treatment market has been dominated by injectable biologics. Drugs like AbbVie's Skyrizi and Johnson and Johnson's Tremfya have set a high bar for skin clearance, and oral alternatives have struggled to compete on efficacy. Bristol Myers Squibb's Sotyktu (deucravacitinib), the first approved TYK2 inhibitor, was supposed to change that calculus when it launched in 2022. It has not quite delivered on that promise. On June 11, 2026, Takeda announced data that suggest the next chapter of the oral psoriasis story may look very different.
In the LATITUDE Atlas Phase 3 trial, Takeda's investigational TYK2 inhibitor zasocitinib demonstrated statistical superiority over Sotyktu on every primary and secondary endpoint in a head-to-head comparison involving 606 adults with moderate-to-severe plaque psoriasis. The headline number is striking: more than 35 percent of patients treated with zasocitinib achieved complete skin clearance, defined as a PASI 100 response, at week 16. That figure was more than 2.5 times the rate seen in the Sotyktu arm. Separation between the two drugs was visible as early as week 8. The safety profile was consistent with prior studies, with no new signals identified.
Why This Result Matters Beyond the Numbers
Head-to-head trials in dermatology are relatively rare. Most drugs in the psoriasis space have been compared to placebo or to older agents like apremilast (Otezla), not to each other. The decision to run a direct comparison against Sotyktu reflects Takeda's confidence in zasocitinib's pharmacological profile and its strategic intent to establish clear differentiation before entering a crowded market. The company paid Nimbus Therapeutics $4 billion upfront for zasocitinib in 2022, one of the largest single-asset deals in autoimmune drug history. The LATITUDE Atlas data are the first direct clinical evidence that the investment may have been justified.
The distinction between the two drugs is rooted in their selectivity. Both are TYK2 inhibitors, but zasocitinib is designed with more than one million-fold greater selectivity for TYK2 compared to other JAK family enzymes. That selectivity matters because TYK2 primarily regulates immune responses, while JAK1, JAK2, and JAK3 are involved in broader biological processes including lipid metabolism and blood cell production. Drugs that inhibit those broader targets carry cardiovascular and hematologic risks that have complicated the JAK inhibitor class. Zasocitinib's allosteric mechanism is designed to maximize TYK2 inhibition while leaving those other pathways largely untouched. The LATITUDE Atlas data suggest that higher selectivity, combined with a once-daily 30mg dose, translates into meaningfully better clinical outcomes than Sotyktu's 6mg formulation achieves.
The Commercial Landscape Zasocitinib Is Entering
The timing of these results is notable. Bristol Myers Squibb recently disclosed plans to pull back Sotyktu's dermatology promotion in many markets, a quiet acknowledgment that the drug has not captured the prescribing momentum the company once anticipated. Sotyktu generated $291 million in revenue in 2025, a respectable figure but well below the blockbuster trajectory that had been projected. Analysts have pointed to a persistent preference among dermatologists for injectable biologics, which deliver higher skin clearance rates than Sotyktu has demonstrated in clinical practice. Zasocitinib's PASI 100 rate of over 35 percent does not yet match what Skyrizi or Tremfya achieve, but it narrows the gap considerably and does so in a once-daily pill rather than an injection.
That distinction matters commercially. The oral segment of the psoriasis market is growing faster than any other, with the number of patients on advanced oral therapy expected to triple over the next decade according to Takeda's own projections. A drug that can deliver substantially better skin clearance than the only approved oral TYK2 inhibitor, while maintaining a clean safety profile, is positioned to capture a meaningful share of that growth. Takeda has indicated it is on track to submit a New Drug Application to the FDA and other global regulators for plaque psoriasis starting this fiscal year.
What Comes Next and What Remains Uncertain
The LATITUDE Atlas data are topline results. Detailed findings have not yet been presented at a medical congress, and the full dataset will be needed before prescribers and payers can fully evaluate the drug's benefit-risk profile. The PASI 100 rate for zasocitinib, while impressive within the oral class, still falls short of what the leading injectable biologics achieve, and that gap will shape how physicians position the drug in their treatment algorithms. Patients who are biologic-naive and prefer an oral option represent the clearest opportunity. Those who have already achieved deep responses on Skyrizi or Tremfya are unlikely to switch.
Beyond psoriasis, Takeda is evaluating zasocitinib in Phase 3 trials for psoriatic arthritis and Phase 2 studies in Crohn's disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa. The IBD data will be particularly consequential. Two prior TYK2 inhibitors, including Sotyktu itself, have failed in ulcerative colitis and Crohn's disease trials. If zasocitinib's superior selectivity and potency translate into efficacy in inflammatory bowel disease, the drug's commercial ceiling expands dramatically. If it does not, the psoriasis indication alone will need to carry the weight of a $4 billion acquisition.
The oral psoriasis market has been waiting for a drug that can genuinely challenge injectable biologics on efficacy. Zasocitinib has not yet cleared that bar, but the LATITUDE Atlas data represent the closest any oral agent has come. Whether that is enough to reshape prescribing habits in a field where dermatologists have grown comfortable with highly effective injections is a question the commercial launch will answer. The clinical data, at least, have given Takeda a credible argument to make.
